Author

James K. Sheffield 1

1 Bristol Myers Squibb Company,Princeton,United States

HEPATIC SAFETY OF OZANIMOD IN ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS PHASE 3 TRIALS

David T. Rubin, Freddy Caldera, Jeffrey Cohen, Stefan Zeuzem, Chun-Yen Cheng, Shabana Ather, Lorna Charles, James K. Sheffield, Axel Dignass

LONG-TERM SAFETY OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC) AND RELAPSING MULTIPLE SCLEROSIS (RMS) STUDIES

Silvio Danese, Douglas C. Wolf, OLGA ALEKSEEVA, Lorna Charles, Sonia Afsari, AnnKatrin Petersen, James K. Sheffield, Hongjuan Li, Diego Silva, Fred Lublin, Bruce A. C. Cree, Jeffrey Cohen, David T. Rubin

SAFETY OF CONCURRENT ADMINISTRATION OF OZANIMOD AND SEROTONERGIC ANTIDEPRESSANTS IN PATIENTS WITH ULCERATIVE COLITIS

Hongjuan Liu, AnnKatrin Petersen, Jean-Frédéric Colombel, Lorna Charles, Michael Silver, James K. Sheffield, Neil Minton, Marc Gleichmann, Jon Riolo, Diego Silva, Bruce A. C. Cree, Robert T. Naismith, Miguel Regueiro

Item 1 - 3 / 3
1